Literature DB >> 29084442

Endocan Concentration in Patients With Primary Hypertension.

Dominika Musialowska1, Edyta Zbroch1, Ewa Koc-Zorawska1, Piotr Musialowski1, Jolanta Malyszko1.   

Abstract

Inflammation and endothelial dysfunction may play an important role in the multifactorial pathogenesis of hypertension. Endocan is also thought to play a role in cell adhesion and inflammatory disorders. The aim of the study was to compare endocan concentrations in patients with primary hypertension and healthy volunteers. There were 104 patients with hypertension (study group) and 21 healthy volunteers (control group). The correlation between endocan, catecholamines, and blood pressure control in patients with primary hypertension and the control group was analyzed. The median endocan concentration in the study group (2.03 ng/mL) was significantly higher than in the control group (1.09 ng/mL, P = .0001). Endocan concentration was correlated positively with renalase ( r = .2, P = .047) and norepinephrine ( r = .25, P = .02). Negative correlation was observed between endocan and body mass index ( r = -.25, P = .016) and leukocyte count ( r = -.36, P = .0004). The present study reports higher plasma endocan concentration in patients with treated, well-controlled primary hypertension compared with healthy volunteers. The higher endocan concentration in the study group may reflect endothelial dysfunction in this population.

Entities:  

Keywords:  catecholamines; endocan; primary hypertension

Mesh:

Substances:

Year:  2017        PMID: 29084442     DOI: 10.1177/0003319717736158

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  8 in total

Review 1.  Methods to evaluate vascular function: a crucial approach towards predictive, preventive, and personalised medicine.

Authors:  Cristina M Sena; Lino Gonçalves; Raquel Seiça
Journal:  EPMA J       Date:  2022-05-20       Impact factor: 8.836

2.  Endocan as a marker of microvascular inflammation in kidney transplant recipients.

Authors:  Yu Ho Lee; Se-Yun Kim; Haena Moon; Jung-Woo Seo; Dong-Jin Kim; Seon Hwa Park; Yang-Gyun Kim; Ju-Young Moon; Jin Sug Kim; Kyung-Hwan Jeong; Sung-Jig Lim; Chan-Duck Kim; Jae Berm Park; Byung Ha Chung; Yeong Hoon Kim; Jaeseok Yang; Hyung-In Yang; Kyoung Soo Kim; Sang-Ho Lee
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

3.  The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis.

Authors:  Tianming Zhao; Yao Kecheng; Xuelei Zhao; Xuehua Hu; Jing Zhu; Yingnan Wang; Jixiang Ni
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

4.  Circulating endocan and preeclampsia: a meta-analysis.

Authors:  Xia Lan; Zhaoming Liu
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

5.  Serum endocan levels in relation to traditional and non-traditional anthropometric indices in adult population.

Authors:  Aleksandra Klisić; Nebojša Kavarić; Vesna Spasojević-Kalimanovska; Jelena Kotur-Stevuljević; Ana Ninić
Journal:  J Med Biochem       Date:  2021-01-26       Impact factor: 3.402

Review 6.  Endocan: A Key Player of Cardiovascular Disease.

Authors:  Jinzhi Chen; Liping Jiang; Xiao-Hua Yu; Mi Hu; Yang-Kai Zhang; Xin Liu; Pingping He; Xinping Ouyang
Journal:  Front Cardiovasc Med       Date:  2022-01-05

Review 7.  Advances in the Role of Endothelial Cells in Cerebral Small Vessel Disease.

Authors:  Tao Bai; Shijia Yu; Juan Feng
Journal:  Front Neurol       Date:  2022-04-11       Impact factor: 4.003

8.  Effect of maternal preconceptional and pregnancy micronutrient interventions on children's DNA methylation: Findings from the EMPHASIS study.

Authors:  Ayden Saffari; Smeeta Shrestha; Prachand Issarapu; Sara Sajjadi; Modupeh Betts; Sirazul Ameen Sahariah; Ashutosh Singh Tomar; Philip James; Akshay Dedaniya; Dilip K Yadav; Kalyanaraman Kumaran; Andrew M Prentice; Karen A Lillycrop; Caroline H D Fall; Giriraj R Chandak; Matt J Silver
Journal:  Am J Clin Nutr       Date:  2020-10-01       Impact factor: 7.045

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.